Delisting risk
NeuroSense Therapeutics (NRSN)
Develops PrimeC, a fixed-dose combination therapy for ALS.
$0.4240
Pre-market−0.00 (−0.21%)
At close$0.4249(+1.14%)
In millions of USD, except per-share figures
| In millions | Q1 FY23Mar 2023 | Q2 FY23Jun 2023 | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3 | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 3 | 3 | |
| Research & development | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 |
| 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |
| General & administrative | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Operating income | −3 | −3 | −3 | −3 | −3 | −3 | −2 | −2 | −2 | −2 | −3 | −3 |
| 0 | −2 | 4 | 0 | −2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Interest income | 0 | 0 | 4 | −4 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest expense | 0 | 0 | 0 | −2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | 0 | 2 | −6 | 2 | 0 | −2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income before tax | −3 | −5 | 1 | −3 | −5 | −1 | −2 | −2 | −2 | −2 | −3 | −3 |
| Net income from continuing operations | −3 | −5 | 1 | −3 | −5 | −1 | −2 | −2 | −2 | −2 | −3 | −3 |
| Net income | −3 | −5 | 1 | −3 | −5 | −1 | −2 | −2 | −2 | −2 | −3 | −3 |
| EPS, basic | −$0.25 | −$0.38 | $0.06 | −$0.19 | −$0.35 | −$0.05 | −$0.11 | −$0.08 | −$0.09 | −$0.09 | −$0.13 | −$0.13 |
| EPS, diluted | −$0.25 | −$0.38 | $0.06 | −$0.19 | −$0.35 | −$0.05 | −$0.11 | −$0.08 | −$0.09 | −$0.09 | −$0.13 | −$0.13 |
| Weighted average shares, basic | 12 | 14 | 14 | 15 | 15 | 18 | 20 | 22 | 25 | 25 | 26 | 26 |
| Weighted average shares, diluted | 12 | 14 | 14 | 15 | 15 | 18 | 20 | 22 | 25 | 25 | 26 | 26 |
| EBITDA | −3 | −6 | 3 | −5 | −3 | −1 | −2 | −2 | −2 | −2 | −3 | −3 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | −3 | −6 | 3 | −5 | −3 | −1 | −2 | −2 | −2 | −2 | −3 | −3 |